Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.29% on an annualized basis producing an average annual return of 19.83%. Currently, Cencora has a market capitalization of $59.16 billion.
Cardinal Health stock hit a new all-time high after mixed earnings, with analyst price target hikes, gene therapy logistics wins and a 29-year dividend growth streak supporting the uptrend.
Cencora’s second quarter was marked by performance that met Wall Street’s expectations on revenue and exceeded consensus on non-GAAP profitability, driving a...
Cencora (NYSE:COR) reported fiscal 2026 third-quarter results marked by double-digit adjusted operating income growth, specialty-business momentum and $1 billion in share repurchases, prompting the pharmaceutical services company to raise its full-year adjusted earnings outlook.
Adjusted operating
Healthcare distributor Cencora (NYSE:COR) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.1% year on year to $84.75 billion. Its non-GAA...
Healthcare distributor Cencora (NYSE:COR) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.1% year on year to $84.75 billion. Its non-GAA...
Healthcare distributor Cencora (NYSE:COR) will be reporting earnings this Wednesday before market hours. Here’s what you need to know. Cencora missed analyst...
McKesson posted strong fiscal 2026 results, raised guidance, boosted buybacks and its dividend, and maintains a Moderate Buy rating from analysts amid its evolving specialty business mix.
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Cencora (NYSE:COR) and its pe...
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...
Over the past six months, Cencora’s stock price fell to $287.06. Shareholders have lost 15.8% of their capital, which is disappointing considering the S&P 50...
Italian healthcare vials and cartridges maker Stevanato Group and U.S. generic and wholesale pharmaceutical company Cencora are two of the best healthcare buys right now.
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...
Cencora’s first quarter results came in below Wall Street’s revenue expectations, and the market responded negatively. Management pointed to several factors ...
Cencora (NYSE:COR) reported higher fiscal second-quarter adjusted earnings and operating income, while management raised its full-year adjusted EPS outlook and said it would resume opportunistic share repurchases. The pharmaceutical distribution and healthcare services company also lowered its full-
